204 related articles for article (PubMed ID: 29467918)
1. Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor.
Yingling JM; McMillen WT; Yan L; Huang H; Sawyer JS; Graff J; Clawson DK; Britt KS; Anderson BD; Beight DW; Desaiah D; Lahn MM; Benhadji KA; Lallena MJ; Holmgaard RB; Xu X; Zhang F; Manro JR; Iversen PW; Iyer CV; Brekken RA; Kalos MD; Driscoll KE
Oncotarget; 2018 Jan; 9(6):6659-6677. PubMed ID: 29467918
[TBL] [Abstract][Full Text] [Related]
2. Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway.
Herbertz S; Sawyer JS; Stauber AJ; Gueorguieva I; Driscoll KE; Estrem ST; Cleverly AL; Desaiah D; Guba SC; Benhadji KA; Slapak CA; Lahn MM
Drug Des Devel Ther; 2015; 9():4479-99. PubMed ID: 26309397
[TBL] [Abstract][Full Text] [Related]
3. Anti-tumor activity of the TGF-β receptor kinase inhibitor galunisertib (LY2157299 monohydrate) in patient-derived tumor xenografts.
Maier A; Peille AL; Vuaroqueaux V; Lahn M
Cell Oncol (Dordr); 2015 Apr; 38(2):131-44. PubMed ID: 25573078
[TBL] [Abstract][Full Text] [Related]
4. Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade.
Holmgaard RB; Schaer DA; Li Y; Castaneda SP; Murphy MY; Xu X; Inigo I; Dobkin J; Manro JR; Iversen PW; Surguladze D; Hall GE; Novosiadly RD; Benhadji KA; Plowman GD; Kalos M; Driscoll KE
J Immunother Cancer; 2018 Jun; 6(1):47. PubMed ID: 29866156
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer.
Rodón J; Carducci M; Sepulveda-Sánchez JM; Azaro A; Calvo E; Seoane J; Braña I; Sicart E; Gueorguieva I; Cleverly A; Pillay NS; Desaiah D; Estrem ST; Paz-Ares L; Holdhoff M; Blakeley J; Lahn MM; Baselga J
Invest New Drugs; 2015 Apr; 33(2):357-70. PubMed ID: 25529192
[TBL] [Abstract][Full Text] [Related]
6. Effects of TGF-beta signalling inhibition with galunisertib (LY2157299) in hepatocellular carcinoma models and in ex vivo whole tumor tissue samples from patients.
Serova M; Tijeras-Raballand A; Dos Santos C; Albuquerque M; Paradis V; Neuzillet C; Benhadji KA; Raymond E; Faivre S; de Gramont A
Oncotarget; 2015 Aug; 6(25):21614-27. PubMed ID: 26057634
[TBL] [Abstract][Full Text] [Related]
7. Galunisertib (LY2157299), a transforming growth factor-β receptor I kinase inhibitor, attenuates acute pancreatitis in rats.
Liu X; Yu M; Chen Y; Zhang J
Braz J Med Biol Res; 2016 Aug; 49(9):e5388. PubMed ID: 27509307
[TBL] [Abstract][Full Text] [Related]
8. Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine.
Capper D; von Deimling A; Brandes AA; Carpentier AF; Kesari S; Sepulveda-Sanchez JM; Wheeler HR; Chinot O; Cher L; Steinbach JP; Specenier P; Rodon J; Cleverly A; Smith C; Gueorguieva I; Miles C; Guba SC; Desaiah D; Estrem ST; Lahn MM; Wick W
Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28481241
[TBL] [Abstract][Full Text] [Related]
9. Transcriptomic evidence for tumor-specific beneficial or adverse effects of TGFβ pathway inhibition on the prognosis of patients with liver cancer.
Desoteux M; Maillot B; Bévant K; Ferlier T; Leroux R; Angenard G; Louis C; Sulpice L; Boudjema K; Coulouarn C
FEBS Open Bio; 2023 Jul; 13(7):1278-1290. PubMed ID: 37195148
[TBL] [Abstract][Full Text] [Related]
10. Transforming Growth Factor β Receptor Type I Inhibitor, Galunisertib, Has No Beneficial Effects on Aneurysmal Pathological Changes in Marfan Mice.
Park JH; Kim MS; Ham S; Park ES; Kim KL; Suh W
Biomol Ther (Seoul); 2020 Jan; 28(1):98-103. PubMed ID: 31284709
[TBL] [Abstract][Full Text] [Related]
11. Disposition and metabolism of [
Cassidy KC; Gueorguieva I; Miles C; Rehmel J; Yi P; Ehlhardt WJ
Xenobiotica; 2018 Apr; 48(4):382-399. PubMed ID: 28436712
[TBL] [Abstract][Full Text] [Related]
12. Combined inhibition of TGFβ and PDGF signaling attenuates radiation-induced pulmonary fibrosis.
Dadrich M; Nicolay NH; Flechsig P; Bickelhaupt S; Hoeltgen L; Roeder F; Hauser K; Tietz A; Jenne J; Lopez R; Roehrich M; Wirkner U; Lahn M; Huber PE
Oncoimmunology; 2016 May; 5(5):e1123366. PubMed ID: 27467922
[TBL] [Abstract][Full Text] [Related]
13. Relative bioavailability of three formulations of galunisertib administered as monotherapy in patients with advanced or metastatic cancer.
Gueorguieva I; Cleverly A; Desaiah D; Azaro A; Seoane J; Braña I; Sicart E; Miles C; Lahn MM; Mitchell MI; Rodon J
Drugs Context; 2016; 5():212303. PubMed ID: 27990167
[TBL] [Abstract][Full Text] [Related]
14. First-in-human dose study of the novel transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma.
Rodon J; Carducci MA; Sepulveda-Sánchez JM; Azaro A; Calvo E; Seoane J; Braña I; Sicart E; Gueorguieva I; Cleverly AL; Pillay NS; Desaiah D; Estrem ST; Paz-Ares L; Holdhoff M; Blakeley J; Lahn MM; Baselga J
Clin Cancer Res; 2015 Feb; 21(3):553-60. PubMed ID: 25424852
[TBL] [Abstract][Full Text] [Related]
15. Selective inhibition of activin receptor-like kinase 5 signaling blocks profibrotic transforming growth factor beta responses in skin fibroblasts.
Mori Y; Ishida W; Bhattacharyya S; Li Y; Platanias LC; Varga J
Arthritis Rheum; 2004 Dec; 50(12):4008-21. PubMed ID: 15593186
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of transforming growth factor beta signaling reduces pancreatic adenocarcinoma growth and invasiveness.
Gaspar NJ; Li L; Kapoun AM; Medicherla S; Reddy M; Li G; O'Young G; Quon D; Henson M; Damm DL; Muiru GT; Murphy A; Higgins LS; Chakravarty S; Wong DH
Mol Pharmacol; 2007 Jul; 72(1):152-61. PubMed ID: 17400764
[TBL] [Abstract][Full Text] [Related]
17. Galunisertib synergistically potentiates the doxorubicin-mediated antitumor effect and kickstarts the immune system against aggressive lymphoma.
Rej A; Paladhi A; Daripa S; Sarkar D; Bhattacharyya S; Mondal I; Hira SK
Int Immunopharmacol; 2023 Jan; 114():109521. PubMed ID: 36470118
[TBL] [Abstract][Full Text] [Related]
18. Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-beta kinase antagonist, in mice.
Bueno L; de Alwis DP; Pitou C; Yingling J; Lahn M; Glatt S; Trocóniz IF
Eur J Cancer; 2008 Jan; 44(1):142-50. PubMed ID: 18039567
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of BMP and of TGFβ receptors downregulates expression of XIAP and TAK1 leading to lung cancer cell death.
Augeri DJ; Langenfeld E; Castle M; Gilleran JA; Langenfeld J
Mol Cancer; 2016 Apr; 15():27. PubMed ID: 27048361
[TBL] [Abstract][Full Text] [Related]
20. Breast cancer anti-estrogen resistance 3 inhibits transforming growth factor β/Smad signaling and associates with favorable breast cancer disease outcomes.
Guo J; Canaff L; Rajadurai CV; Fils-Aimé N; Tian J; Dai M; Korah J; Villatoro M; Park M; Ali S; Lebrun JJ
Breast Cancer Res; 2014 Dec; 16(6):476. PubMed ID: 25499443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
